Targeting tumors using peptides
- Autores
- Scodeller, Pablo David; Asciutto, Eliana Karina
- Año de publicación
- 2020
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- To penetrate solid tumors, low molecular weight (Mw < 10 KDa) compounds have an edge over antibodies: their higher penetration because of their small size. Because of the dense stroma and high interstitial fluid pressure of solid tumors, the penetration of higher Mw compounds is unfavored and being small thus becomes an advantage. This review covers a wide range of peptidic ligands—linear, cyclic, macrocyclic and cyclotidic peptides—to target tumors: We describe the main tools to identify peptides experimentally, such as phage display, and the possible chemical modifications to enhance the properties of the identified peptides. We also review in silico identification of peptides and the most salient non-peptidic ligands in clinical stages. We later focus the attention on the current validated ligands available to target different tumor compartments: blood vessels, extracelullar matrix, and tumor associated macrophages. The clinical advances and failures of these ligands and their therapeutic conjugates will be discussed. We aim to present the reader with the state-of-the-art in targeting tumors, by using low Mw molecules, and the tools to identify new ligands.
Fil: Scodeller, Pablo David. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. University of Tartu; Estonia
Fil: Asciutto, Eliana Karina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de San Martín. Escuela de Ciencia y Tecnología; Argentina - Materia
-
EXTRACELLULAR MATRIX
PEPTIDE-DRUG CONJUGATES
PEPTIDES
PHAGE DISPLAY
SMALL MOLECULES
TUMOR ASSOCIATED MACROPHAGES - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/168184
Ver los metadatos del registro completo
id |
CONICETDig_59f08d2f4ccca9b2770a6295fdba47a7 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/168184 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Targeting tumors using peptidesScodeller, Pablo DavidAsciutto, Eliana KarinaEXTRACELLULAR MATRIXPEPTIDE-DRUG CONJUGATESPEPTIDESPHAGE DISPLAYSMALL MOLECULESTUMOR ASSOCIATED MACROPHAGEShttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1To penetrate solid tumors, low molecular weight (Mw < 10 KDa) compounds have an edge over antibodies: their higher penetration because of their small size. Because of the dense stroma and high interstitial fluid pressure of solid tumors, the penetration of higher Mw compounds is unfavored and being small thus becomes an advantage. This review covers a wide range of peptidic ligands—linear, cyclic, macrocyclic and cyclotidic peptides—to target tumors: We describe the main tools to identify peptides experimentally, such as phage display, and the possible chemical modifications to enhance the properties of the identified peptides. We also review in silico identification of peptides and the most salient non-peptidic ligands in clinical stages. We later focus the attention on the current validated ligands available to target different tumor compartments: blood vessels, extracelullar matrix, and tumor associated macrophages. The clinical advances and failures of these ligands and their therapeutic conjugates will be discussed. We aim to present the reader with the state-of-the-art in targeting tumors, by using low Mw molecules, and the tools to identify new ligands.Fil: Scodeller, Pablo David. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. University of Tartu; EstoniaFil: Asciutto, Eliana Karina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de San Martín. Escuela de Ciencia y Tecnología; ArgentinaMultidisciplinary Digital Publishing Institute2020-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/168184Scodeller, Pablo David; Asciutto, Eliana Karina; Targeting tumors using peptides; Multidisciplinary Digital Publishing Institute; Molecules; 25; 4; 2-2020; 1-241420-3049CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.3390/molecules25040808info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/1420-3049/25/4/808info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:47:54Zoai:ri.conicet.gov.ar:11336/168184instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:47:54.668CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Targeting tumors using peptides |
title |
Targeting tumors using peptides |
spellingShingle |
Targeting tumors using peptides Scodeller, Pablo David EXTRACELLULAR MATRIX PEPTIDE-DRUG CONJUGATES PEPTIDES PHAGE DISPLAY SMALL MOLECULES TUMOR ASSOCIATED MACROPHAGES |
title_short |
Targeting tumors using peptides |
title_full |
Targeting tumors using peptides |
title_fullStr |
Targeting tumors using peptides |
title_full_unstemmed |
Targeting tumors using peptides |
title_sort |
Targeting tumors using peptides |
dc.creator.none.fl_str_mv |
Scodeller, Pablo David Asciutto, Eliana Karina |
author |
Scodeller, Pablo David |
author_facet |
Scodeller, Pablo David Asciutto, Eliana Karina |
author_role |
author |
author2 |
Asciutto, Eliana Karina |
author2_role |
author |
dc.subject.none.fl_str_mv |
EXTRACELLULAR MATRIX PEPTIDE-DRUG CONJUGATES PEPTIDES PHAGE DISPLAY SMALL MOLECULES TUMOR ASSOCIATED MACROPHAGES |
topic |
EXTRACELLULAR MATRIX PEPTIDE-DRUG CONJUGATES PEPTIDES PHAGE DISPLAY SMALL MOLECULES TUMOR ASSOCIATED MACROPHAGES |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/1.6 https://purl.org/becyt/ford/1 |
dc.description.none.fl_txt_mv |
To penetrate solid tumors, low molecular weight (Mw < 10 KDa) compounds have an edge over antibodies: their higher penetration because of their small size. Because of the dense stroma and high interstitial fluid pressure of solid tumors, the penetration of higher Mw compounds is unfavored and being small thus becomes an advantage. This review covers a wide range of peptidic ligands—linear, cyclic, macrocyclic and cyclotidic peptides—to target tumors: We describe the main tools to identify peptides experimentally, such as phage display, and the possible chemical modifications to enhance the properties of the identified peptides. We also review in silico identification of peptides and the most salient non-peptidic ligands in clinical stages. We later focus the attention on the current validated ligands available to target different tumor compartments: blood vessels, extracelullar matrix, and tumor associated macrophages. The clinical advances and failures of these ligands and their therapeutic conjugates will be discussed. We aim to present the reader with the state-of-the-art in targeting tumors, by using low Mw molecules, and the tools to identify new ligands. Fil: Scodeller, Pablo David. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. University of Tartu; Estonia Fil: Asciutto, Eliana Karina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de San Martín. Escuela de Ciencia y Tecnología; Argentina |
description |
To penetrate solid tumors, low molecular weight (Mw < 10 KDa) compounds have an edge over antibodies: their higher penetration because of their small size. Because of the dense stroma and high interstitial fluid pressure of solid tumors, the penetration of higher Mw compounds is unfavored and being small thus becomes an advantage. This review covers a wide range of peptidic ligands—linear, cyclic, macrocyclic and cyclotidic peptides—to target tumors: We describe the main tools to identify peptides experimentally, such as phage display, and the possible chemical modifications to enhance the properties of the identified peptides. We also review in silico identification of peptides and the most salient non-peptidic ligands in clinical stages. We later focus the attention on the current validated ligands available to target different tumor compartments: blood vessels, extracelullar matrix, and tumor associated macrophages. The clinical advances and failures of these ligands and their therapeutic conjugates will be discussed. We aim to present the reader with the state-of-the-art in targeting tumors, by using low Mw molecules, and the tools to identify new ligands. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-02 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/168184 Scodeller, Pablo David; Asciutto, Eliana Karina; Targeting tumors using peptides; Multidisciplinary Digital Publishing Institute; Molecules; 25; 4; 2-2020; 1-24 1420-3049 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/168184 |
identifier_str_mv |
Scodeller, Pablo David; Asciutto, Eliana Karina; Targeting tumors using peptides; Multidisciplinary Digital Publishing Institute; Molecules; 25; 4; 2-2020; 1-24 1420-3049 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.3390/molecules25040808 info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/1420-3049/25/4/808 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Multidisciplinary Digital Publishing Institute |
publisher.none.fl_str_mv |
Multidisciplinary Digital Publishing Institute |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844614524163850240 |
score |
13.070432 |